← All trials
NCT06195228
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2020
- Primary completion
- Apr 30, 2026
- Completion date
- Apr 30, 2027
- First posted
- Jan 8, 2024
- Last posted
- Apr 30, 2024
- Enrollment
- 200
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fudan UniversityLead sponsor
- Fudan UniversityOfficial
- Fudan UniversitySponsor investigator
- Shanxi Medical UniversityCollaborator
- Central South UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiangsu Cancer Institute & HospitalCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Changhai HospitalCollaborator
- Anhui College of Traditional Chinese MedicineCollaborator
- Fujian Medical UniversityCollaborator
- Chinese Academy of Medical SciencesOfficial
- Chinese Academy of Medical SciencesCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Henan Medical UniversityCollaborator
- Inner Mongolia Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.